UK markets close in 4 hours 26 minutes
  • FTSE 100

    7,540.72
    -26.82 (-0.35%)
     
  • FTSE 250

    19,204.69
    -124.89 (-0.65%)
     
  • AIM

    841.35
    -9.37 (-1.10%)
     
  • GBP/EUR

    1.1619
    +0.0004 (+0.04%)
     
  • GBP/USD

    1.2222
    +0.0028 (+0.23%)
     
  • BTC-GBP

    13,908.60
    -328.94 (-2.31%)
     
  • CMC Crypto 200

    400.71
    -10.51 (-2.56%)
     
  • S&P 500

    3,998.84
    -72.86 (-1.79%)
     
  • DOW

    33,947.10
    -482.78 (-1.40%)
     
  • CRUDE OIL

    75.84
    -1.09 (-1.42%)
     
  • GOLD FUTURES

    1,790.20
    +8.90 (+0.50%)
     
  • NIKKEI 225

    27,885.87
    +65.47 (+0.24%)
     
  • HANG SENG

    19,441.18
    -77.11 (-0.40%)
     
  • DAX

    14,404.60
    -43.01 (-0.30%)
     
  • CAC 40

    6,675.54
    -21.42 (-0.32%)
     

What Type Of Shareholders Make Up Shield Therapeutics plc's (LON:STX) Share Registry?

If you want to know who really controls Shield Therapeutics plc (LON:STX), then you'll have to look at the makeup of its share registry. Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. Companies that have been privatized tend to have low insider ownership.

With a market capitalization of UK£78m, Shield Therapeutics is a small cap stock, so it might not be well known by many institutional investors. In the chart below, we can see that institutions own shares in the company. We can zoom in on the different ownership groups, to learn more about Shield Therapeutics.

View our latest analysis for Shield Therapeutics

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Shield Therapeutics?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

As you can see, institutional investors have a fair amount of stake in Shield Therapeutics. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Shield Therapeutics' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Shield Therapeutics is not owned by hedge funds. The company's largest shareholder is Inventages Venture Capital Investment Inc., with ownership of 26%. Aop Orphan International Ag is the second largest shareholder owning 13% of common stock, and Jupiter Fund Management Plc holds about 5.6% of the company stock.

To make our study more interesting, we found that the top 5 shareholders control more than half of the company which implies that this group has considerable sway over the company's decision-making.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.

Insider Ownership Of Shield Therapeutics

While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.

Shareholders would probably be interested to learn that insiders own shares in Shield Therapeutics plc. As individuals, the insiders collectively own UK£3.5m worth of the UK£78m company. This shows at least some alignment, but we usually like to see larger insider holdings. You can click here to see if those insiders have been buying or selling.

General Public Ownership

With a 14% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Shield Therapeutics. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.

Private Equity Ownership

With an ownership of 26%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.

Private Company Ownership

It seems that Private Companies own 14%, of the Shield Therapeutics stock. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.

Next Steps:

While it is well worth considering the different groups that own a company, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 3 warning signs for Shield Therapeutics (of which 1 is a bit concerning!) you should know about.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.